Latest Nasdaq News

Radiopharm Theranostics has received a positive recommendation to escalate the dose of its 177Lu-RAD202 radiotherapeutic in a Phase 1 trial targeting HER2-positive advanced solid tumors, maintaining its timeline to complete dose escalation by year-end 2026.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Global X Management (AUS) Limited has announced the final distribution amounts for 11 ETFs listed on the ASX AQUA Market for the quarter ending 31 March 2026, detailing franking percentages and dividend reinvestment prices.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Nova Minerals has amended its warrant exchange terms, tripling the ratio for Nasdaq-listed warrants to US Holdco warrants as part of its US redomiciliation plan. This adjustment aligns with NYSE listing requirements and signals a strategic step in the company’s transition.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Almonty Industries has commenced commercial production at its flagship Sangdong Mine in South Korea and secured more than US$200 million through Nasdaq IPO and equity offerings to fund expansion projects. Despite rising revenues driven by soaring tungsten prices, the company reported a significant net loss due to non-cash derivative liabilities.

Alliance Nickel is advancing its NiWest project by exploring vat leaching to reduce capital costs and has completed initial gold drilling at Wanbanna, while continuing offtake talks with Stellantis and considering a NASDAQ listing via de-SPAC.

Ovanti Limited has terminated its SPAC transaction with Miluna Acquisition Corp, shifting focus to alternative NASDAQ listing opportunities better aligned with its U.S. expansion strategy. The company is strengthening leadership and accelerating its U.S. growth plans.

Nova Minerals has signed a Scheme Implementation Deed to redomicile to the US, aiming for a primary NYSE listing while retaining a secondary ASX listing via CDIs. The move seeks to align corporate structure with its Alaskan operations and enhance access to US capital markets.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.